Annual report pursuant to Section 13 and 15(d)

Intangible Assets and Impairment of Long-Lived Assets (Details)

v3.24.1
Intangible Assets and Impairment of Long-Lived Assets (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Intangible Assets and Impairment of Long-Lived Assets [Line Items]              
Amortization expense   $ 105,675 $ 109,004        
Traded stock (in Dollars per share)     $ 64.41 $ 252.7 $ 322.24 $ 984.2 $ 1,482
Fair market value     $ 14,674,428 $ 18,872,850      
Loss on goodwill impairment   33,547,278        
Goodwill   $ 0 0        
Impaired assets     3,342,084        
IP R&D asset balance description   This reduced the IP R&D asset balances of its CBR Pharma subsidiary and its 180 LP subsidiary to zero and $9,063,000, respectively, as of December 31, 2022.          
loss on impairment to IP R&D assets $ 9,063,000            
Carrying amount 0            
Income tax benefit $ 2,300,000 $ (2,349,683) (942,749)        
Consolidated IP R&D Assets [Member]              
Intangible Assets and Impairment of Long-Lived Assets [Line Items]              
Goodwill   9,063,000       $ 12,575,780
Carrying amount     12,405,084        
Fair market value of assets     9,063,000        
CBR Pharma [Member]              
Intangible Assets and Impairment of Long-Lived Assets [Line Items]              
Fair market value     1,462,084        
Carrying amount     1,462,084        
Fair market value of assets     0        
180 LP [Member]              
Intangible Assets and Impairment of Long-Lived Assets [Line Items]              
Fair market value     1,880,000        
Carrying amount     10,943,000        
Fair market value of assets     $ 9,063,000